Literature DB >> 18434959

Rafting with the IL-12 receptor.

Daniel W McVicar1.   

Abstract

In this issue of Blood, Kondadasula and colleagues provide important clues for understanding successful cancer immunotherapy by demonstrating an intriguing mechanism through which CD16 synergizes with IL-12 to induce interferon-gamma (IFN-gamma) production by NK cells.

Entities:  

Year:  2008        PMID： 18434959      PMCID： PMC2288709          DOI： 10.1182/blood-2008-01-134627

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Floating the raft hypothesis: lipid rafts play a role in immune cell activation.

Authors:  A Cherukuri; M Dykstra; S K Pierce
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

2.  IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Authors:  Robin Parihar; Julie Dierksheide; Yan Hu; William E Carson
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Regulation of ITAM-positive receptors: role of IL-12 and IL-18.

Authors:  John R Ortaldo; Robin Winkler-Pickett; Jon Wigginton; Meagan Horner; Earl W Bere; Anna T Mason; Narayan Bhat; James Cherry; Michael Sanford; Deborah L Hodge; Howard A Young
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

4.  Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells.

Authors:  K Jiang; B Zhong; D L Gilvary; B C Corliss; E Hong-Geller; S Wei; J Y Djeu
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

5.  A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

Authors:  Robin Parihar; Padma Nadella; Adrian Lewis; Rhonda Jensen; Carrie De Hoff; Julie E Dierksheide; Anne M VanBuskirk; Cynthia M Magro; Donn C Young; Charles L Shapiro; William E Carson
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.